In the dynamic environment of biotechnology trials, the significance of Clinical Data Management systems (CDMs) cannot be overstated. As we navigate the complexities of these trials and the ...
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across monotherapy ...
Leap Therapeutics, Inc. (NASDAQ:LPTX) released significant updates regarding its recent clinical findings and corporate presentation. In a press release titled “Leap Therapeutics Reports Initial ...
Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors ...
ClinChoice extends its 13-year partnership with Medidata to include advanced tools like Clinical Data Studio, enhancing data management and trial efficiency. This collaboration reinforces ClinChoice's ...